REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD)
REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)
This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease (CKD) and existing coronary artery calcification. Sixty participants will be randomized 1:1 to received LoDoCo plus usual care or usual care lone and followed for 24 months.
The primary objective is to evaluate the effect of LoDoCo on CAC progression measured by ECG-gates noncontrast cardiac computed tomography (CT). Exploratory outcomes include valvular calcification, bone mineral density, inflammatory, vascular, and miner-bone biomarkers, cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures, kidney biomarkers, and participant-reported measures of treatment acceptability, adherence, and adverse effects.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The investigators will conduct a randomized, open-label, outcome-blinded, clinical trial in 60 adults with chronic kidney disease (CKD) and existing coronary artery calcification (CAC) Agatston scores of ≥100-1000. Participants will be randomized 1:1 to receive low-dose Colchicine (LoDoCo) plus usual care or usual care alone for 24 months.
The primary objective is to evaluate the effect of LoDoCo on CAC progression over 24 months. CAC will be assessed by ECG-gated noncontrast cardiac computed tomography (CT). Outcomes will include Agatston score and calcium volume. The study will estimate variance, baseline-to-follow-up correlations, and other parameters needed to inform future sample size, treatment duration, and endpoint selection.
Exploratory objectives include evaluating the effects of LoDoCo on aortic valve and mitral annular calcification, CT-derived vertebral bone mineral density, inflammatory biomarkers, vascular calcification biomarkers, and miner-bone metabolism biomarkers. Additional exploratory analyses will examine cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures including ankle-brachial index (ABI) and toe-brachial index (TBI), and kidney outcomes including albumin-creatine ratio (uACR) and estimated glomerular filtration rate (eGFR).
Participant experience with LoDoCo will also be evaluated through assessment of treatment acceptability, adherence, adverse effects, and barriers and facilitators to study participation and retention.
Participants will be followed at baseline, 6 months, 12 months, 18 months, and 24 months for data collection. Participants assigned to the intervention group will undergo additional safety monitoring, including laboratory assessments, throughout the study period.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Paola Lanza, MD
- Telefonnummer: 469-852-9550
- E-Mail: paola.lanza@UTSouthwestern.edu
Studieren Sie die Kontaktsicherung
- Name: Alexandra R Hartman
- Telefonnummer: 614-420-1186
- E-Mail: RESOLVE-CKD@UTSouthwestern.edu
Studienorte
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- University of Texas Southwestern Medical Center
-
Hauptermittler:
- Jing Chen, MD
-
Kontakt:
- Paola Lanza, MD
- Telefonnummer: 469-852-9550
- E-Mail: paola.lanza@UTSouthwestern.edu
-
Kontakt:
- Alexandra R Hartman
- Telefonnummer: 214-645-8294
- E-Mail: alexandra.hartman@UTSouthwestern.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men and women aged 30-<70 years of all race/ethnicity groups
- Chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate (eGFR) 30 to <60 ml/min/1.73m2) or eGFR ≥60 and Urine albumin-to-creatinine ratio (uACR) ≥ 30 mg/g
- Cardiac artery calcification (CAC) Agatston score ≥100-1000
- Ability to provide informed consent.
Exclusion Criteria:
- Current Colchicine therapy
- Hepatic disease
- Established peripheral arterial disease (PAD) defined by self-report or ICD-10 codes
- Congestive heart failure classified as New York Heart Association (NYHA) Functional class III or IV
- Uncontrolled atrial fibrillation with resting heart rate > 100 beats/min
- Dementia defined by self-report or ICD-10 codes (F01-F03)
- Alzheimer's disease defined by self-report or ICD-10 codes (G30)
- Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.
- Immunosuppression, including the use of immunosuppressive medications
- Current use of chemotherapy drugs or active cancer
- Pregnancy/breastfeeding
- Hospitalized within the past 6 months
- Allergic/intolerance to colchicine
- Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir)
- Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)
- Human immunodeficiency virus (HIV) infection
- Gout attack ≥ 1 time per year
- Severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
- eGFR <30 ml/min/1.73m2
- White blood cell count (WBC) <3.0 x10^9/L
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
- Total bilirubin >2 x ULN
- Glucose >300mg/dL
- Uses recreational drugs
- Participant in other conflict clinical trial
- Unable to complete the study measurements
- Unable to undergo to computed tomography (CT)
- Unsafe to participate in this study per investigator's judgement
- Unable to read and speak English or Spanish
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Low-Dose Colchicine (LoDoCo)
Participants will receive low-dose Colchicine (LoDoCo) in addition to usual care. |
Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.
Andere Namen:
Participants will receive usual care according to standard clinical practice and treating physician discretion. |
|
Aktiver Komparator: Usual Care
Participants will receive usual care alone. |
Participants will receive usual care according to standard clinical practice and treating physician discretion. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Coronary Artery Calcification Agatston Scores
Zeitfenster: Baseline, 12 months, 24 months
|
Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Coronary artery calcification will be quantified using the Coronary Artery Calcium (CAC) Agatston Score. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes. |
Baseline, 12 months, 24 months
|
|
Change in Coronary Artery Calcification Volume Scores
Zeitfenster: Baseline, 12 months, 24 months
|
Change in Coronary Artery Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. |
Baseline, 12 months, 24 months
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Exploratory: Change in Aortic Valve Calcification Agatston Scores
Zeitfenster: Baseline, 12 months, 24 months
|
Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Aortic valve calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the aortic valve. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Aortic Valve Calcification Volume Scores
Zeitfenster: Baseline, 12 months, 24 months
|
Change in Aortic Valve Calcification volume (mm3) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Mitral Annular Calcification Agatston Scores
Zeitfenster: Baseline, 12 months, 24 months
|
Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Mitral annular calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the mitral valve annulus. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Mitral Annular Calcification Volume Scores
Zeitfenster: Baseline, 12 months, 24 months
|
Change in Mitral Annular Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Vertebral Bone Mineral Density (BMD)
Zeitfenster: Baseline, 12 months, 24 months
|
Change in vertebral BMD (mg/cm³) will be measured from ECG-gated non-contrast computer tomography (CT) using validated CT-based densitometry methods. BMD will be quantified within the vertebral bodies. Vertebral MBD values range from <80mg/cm³ (very low), 80-120mg/cm³ (low), and >120 mg/cm³ (normal). Lower TBI values are associated with worse outcomes. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in C-Reactive Protein (CRP) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating CRP (mg/L) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Interleukin-1 beta (IL-1β) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating IL-1β levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Interleukin-6 (IL-6) Levels
Zeitfenster: Baseline, 12 months, 18 months
|
Circulating IL-6 levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 18 months
|
|
Exploratory: Change in Interleukin-18 (IL-18) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating IL-18 levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Tumor Necrosis Factor alpha
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating TNF-a levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Interleukin-17 (IL-17) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating IL-17 levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Monocyte Chemoattractant Protein-1 (MCP-1) levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating MCP-1 levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Serum Klotho Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating klotho levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Fetuin A Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating fetuin A levels (ng/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Osteopontin Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating osteopontin levels (ng/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Bone Morphogenetic Protein-2 (BMP-2) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating BMP-2 levels (ng/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Bone Morphogenetic Protein-4 (BMP-4) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating BMP-4 levels (ng/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Bone Morphogenetic Protein-7 (BMP-7) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating BMP-7 levels (ng/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Serum Phosphate levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Serum Calcium Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Parathyroid Hormone (PTH) levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Bone-Specific Alkaline Phosphatase (BSAP) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating serum BSAP levels (ug/L) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Fibroblast Growth Factor 23 (FGF23) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Wnt Inhibitory Factor-1 Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating Wnt Inhibitory Factor-1 (pg/dL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Intact N-Terminal Propeptide of Type I Procollagen (P1NP) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating P1NP levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Sclerostin Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating sclerostin levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating TRAP-5b levels (U/L) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in National Institutes of Health (NIH) Toolbox Fluid Cognition Composite Standard Score
Zeitfenster: Baseline, 12 months, 24 months
|
The NIH Toolbox Fluid Cognition Composite score assesses cognitive functions involved in processing and responding to new information, including attention, executive function, episodic memory, processing speed, and working memory. The age-adjusted Fluid Cognition Composite Standard Score is derived from participant performance on NIH Toolbox cognitive assessments and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Scores of 70 or lower indicate significant impairment, scores around 85 are below average, scores around 100 are average, scores around 115 are above average, and scores around 130 are superior. Higher scores indicate better cognitive performance. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Executive Function
Zeitfenster: Baseline, 12 months, 24 months
|
Executive function will be assessed using the NIH Toolbox Dimensional Change Card Sort Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better executive functioning. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Attention/Inhibitory Control
Zeitfenster: Baseline, 12 months, 24 months
|
Attention and inhibitory control will be assessed using the NIH Toolbox Flanker Inhibitory Control Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better attention and inhibitory control. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Processing Speed
Zeitfenster: Baseline, 12 months, 24 months
|
Processing speed will be assessed using the NIH Toolbox Pattern Comparison Processing Speed test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better processing speed. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Working Memory
Zeitfenster: Baseline, 12 months, 24 months
|
Working memory will be assessed using the NIH Toolbox List Sorting Working Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better working memory. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Episodic Memory
Zeitfenster: Baseline, 12 months, 24 months
|
Episodic memory will be assessed using the NIH Toolbox Picture Sequence Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better episodic memory. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Language/Vocabulary
Zeitfenster: Baseline, 12 months, 24 months
|
Language/Vocabulary will be assessed using the NIH Toolbox Picture Vocabulary Test and Oral Reading Recognition tests. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better language ability. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Southwestern Assessment of Processing Speed (SWAPS) Score
Zeitfenster: Baseline, 12 months, 24 months
|
The SWAPS will be used to assess processing speed. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better processing speed performance. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Texas Card Sorting Test (TCST) Score
Zeitfenster: Baseline, 12 months, 24 months
|
The TCST will be used to assess executive functioning, including cognitive flexibility and concept formation. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better executive functioning. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Phosphorylated tau 217 (p-tau217) levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating p-tau217 levels (pg/mL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Amyloid-beta 42/40 ratio (Aβ42/40) Levels
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating Aβ42 and Aβ40 levels (pg/mL) will be measured using standard clinical laboratory assays and the Aβ42/40 ratio calculated from these measurements and reported as a unitless ratio. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Ankle-Brachial Index (ABI)
Zeitfenster: Baseline, 12 months, 24 months
|
ABI will be measured using semi-automated validated device (simpleABI-600CL). ABI values range from ≤0.90 (Peripheral artery disease), 0.91-0.99 (borderline), 1.00-1.40 (normal).ABI values >1.40 indicate non-compressible arteries, suggestive of arterial stiffness or medial calcification. Both ABI values ≤0.90 and >1.40 are associated with worse outcomes. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Toe-Brachial Index (TBI)
Zeitfenster: Baseline, 12 months, 24 months
|
TBI will be measured using semi-automated validated device (simpleABI-600CL). TBI values range from ≥0.70 (normal), 0.64-0.69 (borderline), and <0.40-0.50 (severe distal arterial disease/critical ischemia range). TBI values <0.70 is a commonly used threshold suggestive of peripheral artery disease. Lower TBI values are associated with worse outcomes. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Percentage of Participants with Ankle-Brachial Index (ABI) ≤0.9 or >1.4
Zeitfenster: Baseline, 12 months, 24 months
|
ABI will be measured using semi-automated validated device (simpleABI-600CL). The percentage (%) of participants with an ABI ≤0.9, indicative of peripheral arterial disease, or an ABI >1.4, indicative of non-compressible arteries suggestive of arterial stiffness or medial calcification will be determined. Higher percentages indicate a greater proportion of participants with abnormal ABI findings. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Urine Albumin-to-Creatine Ratio (uACR)
Zeitfenster: Baseline, 12 months, 24 months
|
Circulating urinary albumin and creatine levels (mg/dL) will be measured using standard clinical laboratory assays. |
Baseline, 12 months, 24 months
|
|
Exploratory: Change in Estimated Glomerular Filtration Rate (eGFR)
Zeitfenster: Baseline, 12 months, 24 months
|
eGFR values (mL/min/1.73m2) will be calculated using the NKF-ASN CKD-Epi refit formula. |
Baseline, 12 months, 24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Jing Chen, MD, University of Texas
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 Jun 15;305(23):2432-9. doi: 10.1001/jama.2011.826.
- Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005 Feb;16(2):520-8. doi: 10.1681/ASN.2004070602. Epub 2004 Dec 22.
- Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31.
- Pan Z, Cheng J, Yang W, Chen L, Wang J. Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials. Eur J Pharmacol. 2022 Jul 15;927:175068. doi: 10.1016/j.ejphar.2022.175068. Epub 2022 May 27.
- Vilaca T, Salam S, Schini M, Harnan S, Sutton A, Poku E, Allen IE, Cummings SR, Eastell R. Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2020 Oct;76(4):521-532. doi: 10.1053/j.ajkd.2020.02.450. Epub 2020 Jul 9.
- Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS; CRIC Study Investigators. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012 Dec;7(12):1938-46. doi: 10.2215/CJN.03500412. Epub 2012 Sep 27.
- Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, Rahman M, Lash JP, Townsend RR, Ojo A, Roy-Chaudhury A, Go AS, Joffe M, He J, Balakrishnan VS, Kimmel PL, Kusek JW, Raj DS; CRIC Study Investigators. Inflammation and Progression of CKD: The CRIC Study. Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1546-1556. doi: 10.2215/CJN.13121215. Epub 2016 Jun 23.
- Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA, Lustigova E, Nessel L, Ford V, Raj D, Porter AC, Soliman EZ, Wright JT Jr, Wolf M, He J; CRIC Investigators. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol. 2017 Jun 1;2(6):635-643. doi: 10.1001/jamacardio.2017.0363.
- Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11.
- Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, Rajgopal Singh R, Elkind MSV, Rangaswami J; American Heart Association. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023 Nov 14;148(20):1636-1664. doi: 10.1161/CIR.0000000000001186. Epub 2023 Oct 9.
- Budoff MJ, Bhandari M, Iskander B, Ghanem AK, Kinninger A, Stark J, Garikapati V, Chilukuri S, Hankil V, Krishnan S, Punnanithinont N, Ichikawa K, Kambalapalli S, Hamal S, Lakshmanan S. Effect of colchicine on progression of known coronary atherosclerosis in patients with stable coronary artery disease: EKSTROM randomized placebo controlled trial. Eur Heart J Cardiovasc Imaging. 2026 Mar 27;27(4):682-692. doi: 10.1093/ehjci/jeag028.
- Absalon-Aguilar A, Rull-Gabayet M, Perez-Fragoso A, Mejia-Dominguez NR, Nunez-Alvarez C, Kershenobich-Stalnikowitz D, Sifuentes-Osornio J, Ponce-de-Leon A, Gonzalez-Lara F, Martin-Nares E, Montesinos-Ramirez S, Ramirez-Alemon M, Ramirez-Rangel P, Marquez MF, Plata-Corona JC, Juarez-Vega G, Gomez-Martin D, Torres-Ruiz J. Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID). J Gen Intern Med. 2022 Jan;37(1):4-14. doi: 10.1007/s11606-021-07203-8. Epub 2021 Nov 9.
- Pan Y, Fan F, Jiang J, Zhang Y. Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3/IL-1beta/IL-6/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 randomized trials. Inflamm Res. 2025 Jun 30;74(1):99. doi: 10.1007/s00011-025-02058-9.
- Yang S, Huang H, Jiang K, Peng Y, Liang Z, Gong X, Li L, Li Y, Zhang B, Chen Y, Yang X. Colchicine inhibits vascular calcification by suppressing inflammasome activation through the enhancement of the Sirt2-PP2Ac signaling pathway. J Biol Chem. 2025 Jul;301(7):110381. doi: 10.1016/j.jbc.2025.110381. Epub 2025 Jun 14.
- Kiraz S, Ertenli I, Arici M, Calguneri M, Haznedaroglu I, Celik I, Pay S, Kirazli S. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol. 1998 Nov-Dec;16(6):721-4.
- Shi M, Zhang X, Li L, Wang Y, Zhao Q, Zhen Y, Huang Y, Liu C. Colchicine reduces inflammatory cytokines and improves symptoms in HFpEF: an observational pilot study. Front Med (Lausanne). 2026 Jan 16;12:1702293. doi: 10.3389/fmed.2025.1702293. eCollection 2025.
- Astiawati T, Rohman MS, Wihastuti T, Sujuti H, Endharti A, Sargowo D, Oceandy D, Lestari B, Triastuti E, Nugraha RA. The Emerging Role of Colchicine to Inhibit NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome and Interleukin-1beta Expression in In Vitro Models. Biomolecules. 2025 Mar 3;15(3):367. doi: 10.3390/biom15030367.
- Liu Q, Yu L, Yin X, Ye J, Li S. Correlation Between Soluble Klotho and Vascular Calcification in Chronic Kidney Disease: A Meta-Analysis and Systematic Review. Front Physiol. 2021 Aug 13;12:711904. doi: 10.3389/fphys.2021.711904. eCollection 2021.
- Henaut L, Massy ZA. New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease. Nephrol Dial Transplant. 2018 Apr 1;33(4):543-548. doi: 10.1093/ndt/gfx379. No abstract available.
- Pang Q, Wang P, Pan Y, Dong X, Zhou T, Song X, Zhang A. Irisin protects against vascular calcification by activating autophagy and inhibiting NLRP3-mediated vascular smooth muscle cell pyroptosis in chronic kidney disease. Cell Death Dis. 2022 Mar 30;13(3):283. doi: 10.1038/s41419-022-04735-7.
- Bundy JD, Chen J, Yang W, Budoff M, Go AS, Grunwald JE, Kallem RR, Post WS, Reilly MP, Ricardo AC, Rosas SE, Zhang X, He J; CRIC Study Investigators. Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study. Atherosclerosis. 2018 Apr;271:53-60. doi: 10.1016/j.atherosclerosis.2018.02.009. Epub 2018 Feb 10.
- Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004 Oct;44(4):680-8.
- Neven EG, De Broe ME, D'Haese PC. Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int. 2009 Mar;75(6):580-2. doi: 10.1038/ki.2008.663.
- Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001 May;21(5):817-24. doi: 10.1161/01.atv.21.5.817.
- Imanishi Y, Furukubo T, Shoji S. Clinical approaches to osteoporosis in patients with chronic kidney disease: A comprehensive review. Endocr J. 2025 Aug 1;72(8):847-862. doi: 10.1507/endocrj.EJ24-0271. Epub 2025 Apr 23.
- Xu B, Ma R, Wu Y, Liu C, Song X. Immune mechanisms in chronic kidney disease-mineral and bone disorder: current insights and therapeutic implications. Front Med (Lausanne). 2025 Oct 9;12:1678640. doi: 10.3389/fmed.2025.1678640. eCollection 2025.
- Zhao Y, Li H, Guo Y. Interleukin family in vascular calcification: molecular mechanisms and therapeutic perspectives. Front Cardiovasc Med. 2025 Sep 1;12:1619018. doi: 10.3389/fcvm.2025.1619018. eCollection 2025.
- Mazzaferro S, De Martini N, Rotondi S, Tartaglione L, Urena-Torres P, Bover J, Pasquali M; ERA-EDTA Working Group on CKD-MBD. Bone, inflammation and chronic kidney disease. Clin Chim Acta. 2020 Jul;506:236-240. doi: 10.1016/j.cca.2020.03.040. Epub 2020 Apr 8.
- Mazzaferro S, Bagordo D, De Martini N, Pasquali M, Rotondi S, Tartaglione L, Stenvinkel P; ERA-EDTA CKD-MBD working group. Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era. Calcif Tissue Int. 2021 Apr;108(4):452-460. doi: 10.1007/s00223-020-00794-0. Epub 2021 Jan 2.
- Lee BT, Ahmed FA, Hamm LL, Teran FJ, Chen CS, Liu Y, Shah K, Rifai N, Batuman V, Simon EE, He J, Chen J. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015 May 30;16:77. doi: 10.1186/s12882-015-0068-7.
- She C, Liu H. Construction and validation of a predictive model for the risk of osteoporosis in patients with chronic kidney disease based on NHANES data. PLoS One. 2025 Feb 6;20(2):e0316494. doi: 10.1371/journal.pone.0316494. eCollection 2025.
- Magagnoli L, Cozzolino M, Caskey FJ, Evans M, Torino C, Porto G, Szymczak M, Krajewska M, Drechsler C, Stenvinkel P, Pippias M, Dekker FW, de Rooij ENM, Wanner C, Chesnaye NC, Jager KJ; EQUAL study investigators. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study. Nephrol Dial Transplant. 2023 Oct 31;38(11):2562-2575. doi: 10.1093/ndt/gfad100.
- Geng S, Kuang Z, Peissig PL, Page D, Maursetter L, Hansen KE. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporos Int. 2019 Oct;30(10):2019-2025. doi: 10.1007/s00198-019-05033-3. Epub 2019 May 31.
- Isakova T, Cai X, Lee J, Xie D, Wang X, Mehta R, Allen NB, Scialla JJ, Pencina MJ, Anderson AH, Talierco J, Chen J, Fischer MJ, Steigerwalt SP, Leonard MB, Hsu CY, de Boer IH, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. J Am Soc Nephrol. 2018 Feb;29(2):579-590. doi: 10.1681/ASN.2017070772. Epub 2017 Nov 22.
- Wang XR, Zhang JJ, Xu XX, Wu YG. Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2019 Nov;41(1):244-256. doi: 10.1080/0886022X.2019.1595646.
- Yamada S, Nakano T. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. J Atheroscler Thromb. 2023 Aug 1;30(8):835-850. doi: 10.5551/jat.RV22006. Epub 2023 May 30.
- Tian L, Jaeger BC, Scialla JJ, Budoff MJ, Mehta RC, Jaar BG, Saab G, Dobre MA, Reilly MP, Rader DJ, Townsend RR, Lash JP, Greenland P, Isakova T, Bundy JD; CRIC Study Investigators. Progression of Coronary Artery Calcification and Risk of Clinical Events in CKD: The Chronic Renal Insufficiency Cohort Study. Am J Kidney Dis. 2025 Jan;85(1):67-77.e1. doi: 10.1053/j.ajkd.2024.06.018. Epub 2024 Aug 16.
- Kurella Tamura M, Tam K, Vittinghoff E, Raj D, Sozio SM, Rosas SE, Makos G, Lora C, He J, Go AS, Hsu CY, Yaffe K; CRIC Study Investigators. Inflammatory Markers and Risk for Cognitive Decline in Chronic Kidney Disease: The CRIC Study. Kidney Int Rep. 2017 Mar;2(2):192-200. doi: 10.1016/j.ekir.2016.10.007. Epub 2016 Oct 31.
- Huang Z, Yaffe K, Li C, Xiao C, Pan Y, Sun X, Anderson AH, He J, Jaar BG, Han H, Kiryluk K, Rahman M, Rao P, Ricardo AC, Shah VO, Srivastava A, Taliercio JJ, Kurella Tamura M, Unruh ML, Weir MR, Lash JP, Bazzano LA, Chen J, Mills KT, Kelly TN; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Chronic Kidney Disease Severity and Risk of Cognitive Impairment. JAMA Netw Open. 2026 Feb 2;9(2):e2559834. doi: 10.1001/jamanetworkopen.2025.59834.
- Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res Ther. 2015 Mar 24;7(1):33. doi: 10.1186/s13195-015-0117-2. eCollection 2015.
- Ayu NP, Kandarini Y, Widiana R, Mahadita GW. Fetuin-A as a risk factor for arteriovenous fistula failure in chronic kidney disease patients with hemodialysis through vascular calcification mechanism: Systematic review and meta-analysis. J Vasc Access. 2026 Jul;27(4):1450-1462. doi: 10.1177/11297298251407274. Epub 2026 Jan 16.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Erkrankungen des endokrinen Systems
- Erkrankungen des Bewegungsapparates
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Ernährungsstörungen
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Chronische Erkrankung
- Krankheitsattribute
- Stoffwechselerkrankungen
- Niereninsuffizienz
- Knochenerkrankungen, Stoffwechsel
- Nebenschilddrüsenerkrankungen
- Atherosklerose
- Arteriosklerose
- Arterielle Verschlusskrankheiten
- Periphere Gefäßerkrankungen
- Avitaminose
- Mangelkrankheiten
- Unterernährung
- Rachitis
- Störungen des Kalziumstoffwechsels
- Mangel an Vitamin D
- Hyperparathyreoidismus, sekundär
- Hyperparathyreoidismus
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Periphere arterielle Verschlusskrankheit
- Niereninsuffizienz, chronisch
- Knochenerkrankungen
- Kalzinose
- Gefäßverkalkung
- Chronische Nierenerkrankung-Mineral- und Knochenstörung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- STU20260896
- 99077 (Andere Kennung: UT Southwestern Medical Center)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IRB approval is required before sharing IPD.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .